Dr. James J. Barber

Executive Advisor

Dr. Barber served as President and CEO of Metabolix, Inc. from January 2000 to May 2007. During this period, he led the transformation of Metabolix from a research boutique to a world renowned, highly regarded leader in "clean tech" and industrial biotechnology, building the company into a multi-disciplinary, industry leading, publicly traded enterprise with a market cap of over $500 million. He negotiated a highly attractive joint venture arrangement with Archer Daniels Midland for commercializing Metabolix's first product platform, MirelTM natural plastics, and took the company public in November 2006.

Prior to joining Metabolix, he served as Global Business Director for the Organometallics and Catalysts business of Albemarle Corporation, with global P&L responsibility for that $100+ million business, and as Representative Director of Nippon Aluminum Alkyls, a joint venture Company between Albemarle and Mitsui Chemicals, Inc. During his tenure with Albemarle, he led the development and implementation of strategies that resulted in the strong growth of Albemarle's polymer catalyst business, including its emerging single-site/metallocene catalyst business.

Prior to his position with Albemarle, Dr. Barber served as Director, Business Development with Ethyl Corporation, with responsibility for acquisitions and managing Ethyl's venture capital activities; as President of Geltech, Inc., a venture capital backed Company focused in the area of precision molded micro optics; and as Chief Operating Officer of Hyperion Catalysis International, a pioneering developer and producer of carbon nanofibers.

Dr. Barber received the American Chemical Society's Henry F. Whalen, Jr. award for Business Development in September 2003. He received a B.S. degree in Chemistry from Rensselaer Polytechnic Institute in 1976 and a Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology in 1980. He currently serves as an advisor to a number of firms, and as a director of Graham Corporation (GHM, NYSE) and Itaconix plc (ITX, London AIM).